Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jiangsu Hanvo Safety Product Co., Ltd. (300952.SZ)
Nantong, JS, CN
Jiangsu Hanvo Safety Product Co., Ltd. engages in the research and development, production, and sale of special safety and health protection products in China. The company offers special safety and health protection products, including gloves, clothing, shoes, and hats; new graphene ultra-fiber materials; protective equipment for medical staff; and medical and daily masks, as well as technical development, consultation, exchange, and other technical services; and technology transfer and promotion services. It is also involved in the wholesale and retail of protective equipment for medical staff. The company exports its products to approximately 50 countries and regions, including Europe, the United States, Japan, and internationally. Jiangsu Hanvo Safety Product Co., Ltd. was founded in 2004 and is based in Nantong, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.65% | -13.89% | +2.55% | -20.30% | +15.70% | -15.93% | +20.24% | +56.91% | +16.03% | -47.35% | -47.35% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%-3.3% Q1'26: -4.1% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%-31.6% Q1'26: -76.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+7.5% ★ Q1'26: -27.1% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+11.1% Q1'26: +3.6% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+5.6% Q1'26: +1.7% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+26.8% Q1'26: +2.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×2.09× Q1'26: 14.58× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
949.52M
est: 888.00M (+6.9%)
|
949.52M
est: 888.00M (+6.9%)
|
893.12M
est: 1.28B (-30.1%)
|
976.96M
est: 1.28B (-23.5%)
|
1.27B
est: 1.24B (+2.7%)
|
1.23B
est: 1.33B (-7.5%)
|
1.55B
1.55B – 1.55B
+16.6% YoY
|
1.93B
1.93B – 1.93B
+24.8% YoY
|
2.31B
2.31B – 2.31B
+19.4% YoY
|
| EBITDA |
148.34M
est: 175.02M (-15.2%)
|
148.34M
est: 174.47M (-15.0%)
|
205.59M
est: 250.85M (-18.0%)
|
203.20M
est: 250.85M (-19.0%)
|
240.33M
est: 242.81M (-1.0%)
|
243.82M
est: 260.72M (-6.5%)
|
303.87M
303.87M – 303.87M
+16.6% YoY
|
379.27M
379.27M – 379.27M
+24.8% YoY
|
452.98M
452.98M – 452.98M
+19.4% YoY
|
| EBIT |
106.78M
est: 124.05M (-13.9%)
|
106.78M
est: 115.01M (-7.2%)
|
150.98M
est: 165.36M (-8.7%)
|
132.14M
est: 165.36M (-20.1%)
|
151.59M
est: 160.06M (-5.3%)
|
136.75M
est: 171.87M (-20.4%)
|
200.31M
200.31M – 200.31M
+16.6% YoY
|
250.02M
250.02M – 250.02M
+24.8% YoY
|
298.61M
298.61M – 298.61M
+19.4% YoY
|
| Net Income |
92.56M
est: 139.54M (-33.7%)
|
92.56M
est: 176.90M (-47.7%)
|
121.70M
est: 186.62M (-34.8%)
|
105.82M
est: 186.62M (-43.3%)
|
116.54M
est: 111.09M (+4.9%)
|
101.90M
est: 95.81M (+6.3%)
|
95.81M
95.81M – 95.81M
+0.0% YoY
|
112.47M
112.47M – 112.47M
+17.4% YoY
|
131.91M
131.91M – 131.91M
+17.3% YoY
|
| SGA |
57.55M
est: 23.85M (+141.3%)
|
57.55M
est: 53.76M (+7.1%)
|
66.67M
est: 77.30M (-13.7%)
|
75.94M
est: 77.30M (-1.8%)
|
84.85M
est: 74.82M (+13.4%)
|
28.07M
est: 80.34M (-65.1%)
|
93.63M
93.63M – 93.63M
+16.6% YoY
|
116.87M
116.87M – 116.87M
+24.8% YoY
|
139.58M
139.58M – 139.58M
+19.4% YoY
|
| EPS |
0.68
est: 0.91 (-25.3%)
|
0.68
est: 0.91 (-25.3%)
|
0.84
est: 0.96 (-12.5%)
|
0.73
est: 0.96 (-24.0%)
|
0.80
est: 0.57 (+40.0%)
|
0.52
est: 0.49 (+5.5%)
|
0.49
0.49 – 0.49
+0.0% YoY
|
0.58
0.58 – 0.58
+17.4% YoY
|
0.68
0.68 – 0.68
+17.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jing Jing Wang | Deputy General Manager | — | female |
| Shuangcheng Wang | Deputy General Manager | — | male |
| Wufen Zhang | Deputy GM, Board Secretary & Director | — | female |
| Xianhua Wang | Chairman of the Board & GM | — | male |
| Xiaodong Ding | Director & Deputy GM | — | male |
| Xiaoning Zhu | Chief Financial Officer, Accounting Supervisor & Non-Independent Director | — | male |
| Yun Lu | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300952.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
